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Abstract: Staphylococcus aureus has been an exceptionally successful pathogen, which is still relevant 
in modern age-medicine due to its adaptability and tenacity. This bacterium may be a causative 
agent in a plethora of infections, owing to its abundance (in the environment and in the normal 
flora) and the variety of virulence factors that it possesses. Methicillin-resistant S. aureus (MRSA) 
strains—first described in 1961—are characterized by an altered penicillin-binding protein 
(PBP2a/c) and resistance to all penicillins, cephalosporins, and carbapenems, which makes the β-
lactam armamentarium clinically ineffective. The acquisition of additional resistance determinants 
further complicates their eradication; therefore, MRSA can be considered as the first representative 
of multidrug-resistant bacteria. Based on 230 references, the aim of this review is to recap the history, 
the emergence, and clinical features of various MRSA infections (hospital-, community-, and 
livestock-associated), and to summarize the current advances regarding MRSA screening, typing, 
and therapeutic options (including lipoglycopeptides, oxazolidinones, anti-MRSA cephalosporins, 
novel pleuromutilin-, tetracycline- and quinolone-derivatives, daptomycin, fusidic acid, in addition 
to drug candidates in the development phase), both for an audience of clinical microbiologists and 
infectious disease specialists. 
Keywords: Staphylococcus; MRSA; SSCmec; colonization; typing; lipoglycopeptides; oxazolidinones; 
ceftaroline; daptomycin; pleuromutilin  
 
1. Introduction 
Taxonomically, the genus Staphylococcus is included in the Micrococcaceae family within the 
phylum Actinobacteria [1,2]. They are Gram-positive, catalase-positive, and bacitracin-resistant cocci 
[3]. Staphylococci are non-spore forming bacteria, nevertheless they are very common in nature and 
they can survive in a variety of harsh environments outside of the body, in addition to being resistant 
to many disinfecting agents [1,2,4,5]. Staphylococcus aureus is coagulase-positive, which is another 
important differentiating factor between this species and coagulase-negative staphylococci (CoNS; 
e.g., S. epidermidis) [1,6]. S. aureus (and its methicillin-resistant counterpart) may colonize various 
mucosal sites of the body: the nostrils (nares), throat, dedicated areas of the skin (including the axilla, 
groin, and perineum; these skin surfaces are usually moist), and rectum. S. aureus is an exceptionally 
successful pathogen, which is still relevant and dangerous in modern age-medicine [7]. Furthermore, 
small-colony variants of S. aureus (SCVs; a sub-population of bacteria that are naturally present in 
small quantities) allow for chronic, recurrent, and antibiotic-resistant infections to develop and 
persist in the host [4,8]. In this morphotype of S. aureus, mutations occur in the genes that regulate 
metabolic activity, resulting in the so-called “dwarf colony” phenotype on agar plates, while, in vivo, 
these bacteria can withstand otherwise lethal doses of antibiotics [9,10]. S. aureus is an important 
causative agent of bacteremia and, though hematogenic dissemination, additional infections, such as 
infective endocarditis, complicated skin and soft tissue infections (cSSTI), osteoarticular infections, 
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prosthetic device infections (PDI), and pleuropulmonary infections may also occur. In addition, S. 
aureus has significant roles in other pathologies (epidural abscesses, meningitis, toxic shock syndrome 
(TSS), urinary tract infections (UTIs), septic thrombophlebitis, etc.) [5,7,9,11–13]. Invasive infections 
that are caused by this pathogen affect all age groups, while the prevalence of these infections is 
somewhat higher in infants and patients over 65 years of age [5,12,14–16]. 
The main virulence factors of these bacteria play different functions in various stages of their 
replication; e.g., in the exponential-growth phase, surface proteins, such as Protein A, elastin-binding 
protein, collagen-binding protein, fibronectin-binding protein, and clumping factor play major roles 
[17–21]. In contrast, during the stationary phase, secreted proteins, such as enterotoxin B, toxic shock 
syndrome toxin-1 (TSST-1), and α-toxin are the most prevalent [17–21]. Various regulatory pathway 
mediate the expression of these virulence factors, mainly by the agr (accessory gene regulator) system 
[22]. This regulatory system responds to the density of the bacterial populations (this phenomenon is 
termed quorum sensing (QS)) [23]. At the onset of infection (where rapidly-multiplying bacteria are 
present, and the density of the population is low), the expression of surface-bound adhesins is more 
pronounced, while, if high population density is locally achieved (in the stationary phase, generally 
at the site of infection), the secretion of bacterial toxins commences [5,17,21,22,24]. 
Before the advent of antibiotics, severe infections with S. aureus were usually considered to be a 
death sentence [25]. These infections became successfully treatable after the paradigm-altering 
discovery of penicillin by Alexander Fleming, due to the uniform susceptibility of these bacteria [26]. 
However, this did not last, as only few years after the introduction of penicillin, the first resistant 
strains were described (nowadays, more than 95% of S. aureus isolates are resistant to penicillin), 
producing an extracellular enzyme, called penicillinase [27,28]. Reacting to the resistance trends, 
pharmaceutical companies developed methicillin, which may be considered the prototype of anti-
staphylococcal penicillins (a group currently consisting of oxacillin, cloxacillin, dicloxacillin, nafcillin 
(these drugs are available in the US) and flucloxacillin [available in some parts of Europe and 
Australia]) [29,30]. Shortly, strains also developed a resistance mechanism against these agents, 
which was unrelated to the production of penicillinases. The phenomenon of methicillin-resistance 
in S. aureus (MRSA) strains was first described in 1961, and they were characterized by an altered 
penicillin-binding protein (PBP2a, see Section 3.), which had reduced affinity for methicillin and, 
thus, could continue peptidoglycan synthesis uninterrupted in the presence of this drug [31–33].  
However, this, had more detrimental ramifications than resistance to “just” one antibiotic: 
MRSA strains show resistance to all penicillins, cephalosporins, and carbapenems, making the β-
lactam armamentarium clinically ineffective [33]. This was especially problematic in sensitive age 
groups (during pregnancy and in children), as many other antibiotics are not suitable to be used due 
to their teratogenicity or their severe side effects [12,34]. Furthermore, over time, MRSA strains 
became resistant to a number of other antibiotic classes (e.g., fluoroquinolones, macrolides, 
aminoglycosides, clindamycin). For this reason, MRSA strains, coupled with other resistance 
mechanisms, may be considered as the first class multidrug resistant (MDR) pathogens [35–37]. 
Nowadays, targeted antibiotic therapy, which is aided by antimicrobial susceptibility testing results 
(as a part of antibiotic stewardship), is of critical importance. In addition, the preservation and 
prudent use of these drugs is a clear agenda, both from the healthcare and regulatory perspectives. 
There is a debate on whether he imprudent use of antibiotics at that time catalysed the appearance of 
MRSA, or whether the development of penicillin-resistance to methicillin-resistance was a clear 
evolutionary path, which was irrespective of drug utilization levels [38–44]. Unsurprisingly, studies 
comparing hospital costs, the length of hospital stay, and mortality rate related to methicillin-
susceptible and resistant S. aureus infections clearly highlight that MRSA infections are associated 
with a greater burden on healthcare infrastructure [45,46]. Delayed therapy may increase the risk for 
the development of MRSA bacteremia: despite the availability of active antibiotics for the treatment 
of these infections (see Section 4.), it is still a major cause of morbidity and mortality worldwide [47–
50]. 
Between the 1960–1970s, MRSA infections were predominantly associated with nosocomial 
outbreaks, which affect hospitalized patients or outpatients that frequently attend hospitals [51]. 
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These infections, termed hospital-acquired MRSA (HA-MRSA) were in majority until the end of the 
1970’s. The first successful clone, whose global spread was described, was the phage type 83A 
(sequence type 250 [ST250]; see Section 3.), which was gradually replaced by other clones during the 
1980s [52,53]. The epidemiology of MRSA infections shifted during the 1990s, when the number of 
infections, lacking the risk factions that are associated with acquiring HA-MRSA increased 
significantly [54]. This has led to the emergence of community-associated MRSA (CA-MRSA) 
infections, including infections that were diagnosed in outpatients or inpatients within two days of 
hospitalization, not being associated with previous healthcare-related risks (long-term care facilities, 
hospitalization in the previous year, surgical procedures, hemodialysis, presence of an indwelling 
catheter, or a percutaneous device) or a previous isolation of MRSA from the same patient (see CDC-
defined case-definitions of CA-MRSA) [55,56]. The spread of CA-MRSA has been reported from 
basically every region on the planet and this has become the principle type of MRSA infection in the 
past 10–20 year, owing to successful clones [57,58]. In both MRSA-subtypes, the emergence of 
additional resistance mechanisms (both due to mutations and acquired resistance determinants) has 
been a constant feature [31,40]. From the 1980s and onward, several antibiotics appeared on the 
market, allowing for the better management of infections, nonetheless, the emergence and spread of 
resistance to these drugs has been observed throughout the years [16]. For example, the resistance 
against fluoroquinolones has increased drastically not long after the introduction of ofloxacin and 
ciprofloxacin [59,60]. In fact, fluoroquinolone-resistance was considered as a hallmark of HA-MRSA 
bacteria, thus, it was used as a method of differentiation among the MRSA strains of nosocomial and 
community origin [55,61]. The differentiation between HA- and CA-MRSA is further complicated by 
the phenomena of the so-called community-onset MRSA (CO-MRSA) infections: these infections are 
thought to be related to HA-MRSA infections (they are also called “escaped” or “feral” MRSA strains, 
because they have escaped from the nosocomial environment), which are associated with the 
increasing use of outpatient intravenous (parenteral) antimicrobial therapy (OPAT) and the 
management of complex infections in the home of the patients [55,62,63]. 
S. aureus is also a significant cause of morbidity and mortality in animals. This is especially 
important for the livestock/food industry, as outbreaks may result in pronounced economic losses 
[64]. Livestock-associated MRSA (LA-MRSA) strains were first described in the beginning of the 
2000s in livestock; today, it is well-known that veterinary doctors, people working on farms or at 
slaughterhouses, or basically anyone who comes in contact with any animal or pet, which is carrying 
LA-MRSA is at risk of transmission [65]. LA-MRSA has no relevant host-specificity, it can colonize 
any animal, although cattle, pigs, and poultry are reported to be the main reservoirs [65–67]. LA-
MRSA initially presented itself as a conundrum to scientists, as they were non-typable with pulsed-
field gel electrophoresis (PFGE; after digestion with the SmaI restriction enzyme) at the time of their 
discovery. After additional studies, it was revealed that this new lineage of S. aureus belongs to clonal 
complex 398 (CC398) [68]. No difference in the pathogenicity of LA-MRSA—compared to the 
nosocomial- or community-acquired types—was found [65,69]. The epidemiological data is scarce 
regarding the prevalence of LA-MRSA infections, some reports suggest that they account for 
approximately 15% of MRSA SSTI in the community and 1–2% of infections that were isolated in the 
hospital environment [70]. 
The landscape of nosocomial and MDR pathogens in clinical practice has drastically changed 
since the beginning of the 21st century (i.e., the global spread of toxin-producing Clostridium difficile 
[71–73], multidrug-resistant Neisseria gonorrhoeae [74], and the concerning rise of extended-spectrum 
β-lactamase (ESBL)- and carbapenemase-producing Enterobacteriaceae [75,76]); however, MRSA has 
proven to be one of the most persistent drug resistant pathogens in both the healthcare and 
community setting [56]. Based on the assessments of the US Centers for Disease Control and 
Prevention (CDC), after considering various factors, such as treatability, mortality, burden on the 
healthcare-infrastructure and the community, prevalence and increasing trends of resistance, 
preventability and transmissibility, in addition to the drugs that are currently in the pipeline, MRSA 
has been classified as a serious threat [77]. S. aureus is included in the group of “ESKAPE” bacteria, 
which comprise the MDR pathogens that are currently considered as the biggest concern for 
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humanity [35,40,78]. Although there is a relative abundance of the different antibiotic-groups for the 
treatment of MRSA (this is one reason why pharmaceutical companies became more focused on the 
development of new drugs against MDR Gram-negatives in the 21st century, see Section 4.) [79], one 
should not be complacent about the current situation [80–82]. This is underlined by the recent WHO 
report, urging drug companies to invest and target various drug-resistant bacteria (causing serious 
morbidity and mortality worldwide) during antibiotics research, which also includes MRSA [83,84]. 
2. MRSA Colonization and Screening 
In the current climate of the antibiotic-resistance crisis, it is important for laboratories to monitor 
the trends and mechanisms of resistance in S. aureus (especially methicillin/oxacillin-resistance), in 
addition to the spread of successful clones [85]. The detection of carriage is another important 
hallmark in infection control and the successful eradication of MRSA, which is among the 
responsibilities of clinical microbiology/public health laboratories [86]. This is further highlighted by 
the fact that, in most cases, colonization (lasting for periods of few months to a few years) precedes 
infection [87]. Colonization with MRSA is a well-known risk factor in developing an MRSA infection 
in adults and children; this is especially true for patients who acquire MRSA colonization in the 
nosocomial setting, where the risk of developing an MRSA infection as a result is around 30% [85,88]. 
MRSA is usually spread by direct skin-to-skin contact and this may occur during hospital admission, 
transfer, or other healthcare-related contact; however, the role of shared public spaces (e.g., 
dormitories, gym, barracks, etc.) was also noted [86]. A set of bacterial determinants influence 
carriage (adhesive proteins (SdrC, SdrD, and SdrE), clumping factor, fibronectin binding proteins 
(clfA, clfB, fnbA, fnbB), adhesive molecules (altA, eap), cell surface-remodeling enzymes (sceD, oatA, 
altA), and biofilm formation) and host-specific factors (the integrity of the skin barrier, chronic 
inflammation, toll-like receptor 2 (TLR-2) gene polymorphisms, antimicrobial peptides (AMPs), such 
as cathelicidins, defensins, proteolysis-inducing factor, lactoferrin, RNase 7; individual variation in 
cortisol and 25-OH-D-vitamin levels, HLA-DR3 allele) [86,88]. Based on the patterns of carriage, 
persistent, intermittent, and non-carriage has been described. The so-called “culture rule” was 
established for the appropriate detection of these carriage types: based on two nasal cultures taken a 
week apart, the number of positive cultures (two: persistent, one: intermittent and zero: non-carrier) 
was indicative of carriage status [89]. Screening should be performed from multiple sites of the body 
to ensure the adequate pickup rate of this pathogen. Additionally, it would be ideal to simultaneously 
process these samples for financial considerations [90]. 
The most frequently used methods for MRSA screening are still culture-based [91]. Generally, 
all of these methods include a preliminary step of selective enrichment in a broth medium, followed 
by culturing on selective solid media (containing oxacillin/cefoxitin) (Figure 1.) [92]. Several studies 
have highlighted the relevance of enrichment, showing that the direct plating of the sample onto 
MRSA-selective agars has inadequate selectivity and sensitivity [93]. Instead of methicillin 
(nowadays only having theoretical importance) or oxacillin (the use of which is not recommended 
anymore, because it is affected by other resistance mechanisms that are related to β-lactams), the use 
of cefoxitin disks, as a surrogate agent, is recommended, both by the Clinical Laboratory Standards 
Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines [94–96]. Clearly, any anomaly that was detected around the cefoxitin (<22 mm zone 
diameter; together with the knowledge of local epidemiological data) during routine antimicrobial 
susceptibility testing (AST) should be investigated if the patient’s MRSA carriage is unknown [94–
96]. Around 48 hours are needed for identification (considering enrichment and growth on selective 
solid media) and the reporting of results using culture-based methods [91]. If cefoxitin susceptibility 
testing is not performed in parallel, another day may be required to perform AST. Alternative 
methods, such as latex agglutination, can also be used: these tests detect the product of the mecA gene 
(the PBP2a protein, found in the cell membrane of MRSA). The disadvantage of these methods is that 
the product of the mecC gene (see Section 3.) is not detected, which may lead to false-negative results. 
Additionally, selective enrichment prior to detection with latex agglutination is still recommended. 
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With the advent of molecular methods (polymerase chain reaction, PCR), the reporting of results 
on the same day has become possible, although this means that the samples must reach the laboratory 
in time for batch processing [91]. These methods may include in-house PCRs (with the design of 
target-specific primers for the relevant genes) or commercially available systems (e.g., the Cepheid 
Xpert MRSA assay) [91,97]. Interestingly, several reports have also indicated the usefulness of matrix-
assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the 
detection of MRSA, together with the selective enrichment and/or PBP2a’ latex agglutination, which 
reduces the turnaround-time (TAT) for result reporting [92,98]. Appropriate logistics and 
infrastructure are needed to support the effectiveness of MRSA screening: including swift transport 
of the specimens from the ward to the microbiology laboratory, reporting of results to the clinicians 
in a clinically-relevant timeframe, and prompting action from the part of the infection control unit 
(including isolation and/or decolonization of the patient) [91,97]. In summary, the methods that are 
used for the detection of MRSA-colonization are usually determined by the settings of the healthcare 
institution (i.e., number of beds and patient characteristics) and the facilities of the clinical 
microbiology laboratory (i.e., the expected sample number), the required TAT for detection and 
monetary constraints [91,92,97]. Currently, there is no study confirming that the cost/benefit ratio and 
the overall benefits of PCR screening could surpass the culture-based techniques. Besides clinical 
microbiology laboratories, the abovementioned techniques are also used in the MRSA screening in 
livestock, based on the same principles. However, for national-level surveillance purposes, or during 
the investigation and follow-up of an outbreak, molecular methods (PCR) are the most frequently 
used, being complemented with genotyping (see Section 3.). 
 
Figure 1. Cefoxitin-susceptible S. aureus on Mueller-Hinton-agar (antibiotic susceptibility-testing 
based on the Kirby-Bauer method) (left), Methicillin-resistant S. aureus (MRSA) screening using 
mannitol-salt agar (MSA) using cefoxitin disks (right). 
3. Genetics of MRSA, Typing Methods 
By definition, the MRSA strains are S. aureus isolates that possess an altered penicillin-binding 
protein (namely PBP2a or PBP2c, encoded by the mecA/mecC genes; the expression of which is 
regulated by mecI and mecR1), a protein that is essential to bacterial cell wall synthesis, resulting in 
non-susceptibility to all β-lactam antibiotics, with the exception of anti-MRSA cephalosporins 
(ceftaroline and ceftobiprole) [53,99]. The resistance that is caused by modifications in the PBPs is not 
a unique phenomenon to S. aureus, as similar mechanisms are responsible for ampicillin-resistance in 
Enterococcus faecium (PBP5) [100] and the penicillin non-susceptibility in Streptococcus pneumoniae 
(PBP1x mosaic genes) [101]. In addition, these microorganisms can easily acquire resistance to 
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additional antibiotic groups due to horizontal gene transfer [102]. The genes that encode for these 
proteins can be found in a chromosomal genetic element, called staphylococcal chromosomal cassette 
mec (SCCmec), which was found as a fundamental discovery by Hiramatsu et al. [103]. SCCmec is 
integrated into orfX (a staphylococcal gene of unknown function) and in addition to the mecA or mecC 
complex (which is a 30–60 kbp genetic element), it contains two recombinase genes (ccrA and ccrB), 
and is responsible for the integration/excision of this genetic element from the staphylococcal 
chromosome [104]. 
Currently, twelve allotypes of SCCmec (namely I–XII) have been defined, which are separated 
based on the type of ccr gene complex (responsible for site-specific excision and the insertion of the 
gene cassette) and the type of mec complex [102,105]. Presumably, this number is only going to 
increase (with more subtypes emerging), because the use of novel sequencing technologies (i.e., next-
generation sequencing, NGS) with higher discriminatory power will also undoubtedly bring forth 
changes in this field, just like after the first time the S. aureus genome was first sequenced in 2001 
[106,107]. In the 1980–1990s, CA- and HA-MRSA strains could be safely distinguished by phenotypic 
characteristics: the HA-MRSA strains were more frequently MDR strains (resistant to antibiotics 
other than β-lactams), while the CA-MRSA strains were predominantly susceptible to non-β-lactams 
[31]. However, this distinction between the two groups has eroded slowly over time [108]. Nowadays, 
a useful method for the differentiation of CA- and HA-MRSA strains is based on molecular methods. 
When compared to the community-associated strains, HA-MRSAs carry a larger SCCmec cassette and 
they usually belong to the I, II, or III allotypes [51,85,102]. In contrast, the CA-MRSA strains are 
associated with smaller genetic elements (carrying the mecA/C gene), which is thought to be 
influencing their mobility, belonging to the IV, V, or VII allotypes [57,61,85,102]. The detection of 
Panton–Valentine leukocidin (PVL) is another possible way for distinction, which is a characteristic 
toxin of the species [17,108,109]. Although the clinical role and significance of this toxin in the 
pathogenesis of the diseases that is caused by S. aureus is not clear, the presence of the toxin is much 
more frequent in the CA-MRSA strains [109–111]. 
When compared to mecA, mecC is a novel variant of the gene responsible for methicillin-
resistance (encoded on a novel type XI SCCmec element [99]), which was first described in 2007 
(although retrospective studies with old strain collections have found that these variants were 
probably around, ever since MRSAs were known) [112]. mecC shows around 70% nucleotide 
sequence homology with the classical mecA gene, resulting in false negative results in molecular 
detection systems [113]. Following 2010, mecC-positive MRSA strains are increasingly being reported 
in both humans and animal infections [113,114]. In fact, some studies suggest a zoonotic background 
and transmission for this allotype. There is limited data in the literature regarding the efficacy of 
detecting mecC-positive strains, using classical (i.e., phenotypic) AST methods. Another reason for 
the use of cefoxitin as a surrogate for MRSA-detection is that it was found to be more reliable in the 
detection of mecC-positive MRSAs (see Section 2.) [96]. Owing to the genetic nature of the SCCmec 
cassette (being a mobile genetic element), methicillin-resistant CoNS may also possess the mecA/mecC 
genes, which may result in dual colonization with methicillin-resistant CoNS and methicillin-
susceptible S. aureus [112]. 
Beginning from the 1980s (after the global spread of some successful MRSA clones), the need for 
the observation and characterization of the epidemic MRSA clones has become of pivotal importance 
[85]. Five different methods, with various advantages and disadvantages associated with each 
method, currently perform the typing of successful epidemic clones. Initially, phage typing was used 
for the differentiation of various MRSA strains, owing to their differential susceptibility of lytic 
phages (differentiating strains into phage types) [52]. Multi-locus sequence typing (MLST) is 
sequence based genotyping method, which is based on the single nucleotide polymorphisms of seven 
distinct S. aureus housekeeping genes (covering around 450 bps of genetic material) [115]. Using the 
allelic profile of various strains, a sequence type (e.g., ST44) can be assigned. If strains have identity 
at ≥5 housekeeping genes, they are assigned to the same clonal complex (e.g., CC78). Nowadays, the 
lineages of various epidemic strains are considered based on the CC identity [99]. The advantage of 
MLST is the ability to monitor variations over a longer time period to follow the evolution of the 
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epidemic clones and its usefulness in scientific analysis; however, it may be too expensive for routine 
laboratories [85]. Pulse-field gel electrophoresis (PFGE) is more suitable for the evaluation of rapid 
changes over a shorter time period [116]. During this procedure, S. aureus genomic DNA is digested 
by SmaI restriction enzyme and the resulting fragments are then separated by pulsed-field 
electrophoresis in an agarose gel. The clustering of strains is performed based on >80% similarity, 
separating clones into various PFGE types (e.g., C1, D5, G10) [85,116]. Several national and 
international PFGE databases are available for the comparative analysis of epidemic MRSA strains 
[1,116,117]. Protein A typing (spa typing) is an inexpensive method, which is based on the sequence 
analysis of variable number tandem repeats (VNTRs) in the encoding gene of this protein (spa), while 
also taking the number of repeat variations and point mutations into account (e.g., t011, t899) [118–
120]. As a novelty, some studies have reported in the use of MALDI-TOF MS for the rapid 
discrimination of epidemic clones of MRSA, based on the association of their measured protein peaks 
(for an excellent review on the background of mass spectrometry, see [121]) and their spa types 
[118,122]. Whole-genome sequencing (WGS) is currently considered to be the gold standard as a 
molecular typing tool for the investigation of MRSA outbreaks [123]. This method has the most 
discriminating profile, allowing for the analysis of core genome multi-locus sequence typing 
(cgMLST) data [106]. The price of the sequencing machines and the lack of the adequate 
bioinformatics pipeline hinders the extensive use of this method, therefore sequencing is usually 
limited to reference laboratories [106,123]. 
4. Treatment Considerations, Emerging Concepts  
Table 1 presents the currently available drugs for the therapy of MRSA-infections. Following the 
emergence of MRSA in clinical practice, the significance of non-β-lactam-antibiotics (notably 
trimethoprim-sulfametoxazole [SMX/TMP] and doxycycline) has increased, especially in the therapy 
of cSSTI that is caused by CA-MRSA infections [45,124,125]. However, acquired resistance against 
the abovementioned drugs developed rapidly. At the end of the 1980s, MRSA strains with resistance 
against all other drugs except vancomycin were very common [108]. Resistance against SMX/TMP 
may occur due to alternative metabolic pathways of folate synthesis (due to point mutations in the 
dhfr gene) [126,127], while various tet efflux pumps and target modification (30S ribosomal RNA) 
mainly affected doxycycline [128]. Resistance to fluoroquinolones also frequently occurs in MRSA 
and is due to mutations in the quinolone-resistance-determining region (QRDR) of DNA gyrase (gyrA 
and gyrB) and topoisomerase IV (grlA and grlB in S. aureus) [59,60]. In addition, the overexpression 
of the Major Facilitator Superfamily (MFS) efflux pumps NorA and NorB contributes to high-level 
fluoroquinolone resistance (not to mention, the resistance to several antiseptics and disinfectants) in 
S. aureus [129–132]. 
For this reason, vancomycin (dosing generally includes a 25–30 mg/kg loading dose, followed 
by 15–20 mg/kg maintenance dose) was the “gold standard” of anti-MRSA-therapy for a very long 
time [133–135]. It exerts potent bactericidal activity in a concentration- and time-dependent manner 
against Gram-positive bacteria (including Flavobacterium spp. (which are Gram-negative) and 
excluding Erysipelotrix spp., Lactobacillus spp., Leuconostoc spp., and Nocardia spp. (due to intrinsic 
resistance to the drug)) [133–135]. However, the use of vancomycin also had pronounced drawbacks: 
it could only be parenterally used, as it is not absorbed in the gastrointestinal tract (which may even 
be useful in some cases; see therapy of C. difficile infections), its side effect profile (nephrotoxicity, 
ototoxicity, red man syndrome due to histamine liberation, etc.), and the subsequent need for 
therapeutic drug monitoring (TDM) [135,136]. The biggest concern is the phenotype of vancomycin-
resistant S. aureus (VRSA; MIC ≥ 16 μg/mL), which has acquired the vanA gene from vancomycin-
resistant Enterococcus spp. (where the prevalence of this gene is much higher) [100,137,138], while the 
vancomycin intermediate-resistant S. aureus (VISA; MIC, 4–8 μg/mL) strains are characterized by 
reduced susceptibility, owing to a thickened cell wall, which is capable of binding the drug and 
reducing its diffusion into the cell [139]. Resistance against teicoplanin characterizes a similar 
phenotype (Targocid®  [US/EU]; another member of the glycopeptide group of antibiotics; 800 mg/12 
h), but not vancomycin, which is caused by the presence of the vanB gene [140]. It is important to note 
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that the step-wise progression of VISA-to-VRSA does not occur, as the two resistance types have 
completely different mechanisms [139]. Luckily, the prevalence of VRSA remains very low, and most 
published reports detected strains that were colonizers, not the causative agents of infection [137,138]. 
An additional phenotypic group that warrants attention is the heterogeneous vancomycin 
intermediate-resistant S. aureus (hVISA; 1–4 μg/mL): these bacteria are described as being at a stage 
prior to the development of intermediate-level resistance [141]. With continuous selection pressure 
from vancomycin treatment, the environment favors the selection of VISA clones, which leads to a 
unanimous intermediate-resistant population. Based on the available experimental evidence, 
multiple, sequential mutations (involving various regulatory systems of cell wall homeostasis and 
remodeling) are required [141]. The role and clinical significance of hVISA is not yet understood, as 
there are no standardized methods to appropriately study this phenomenon in clinical microbiology 
laboratories [142]. 
Table 1. Summary of advantages and disadvantages for various drug classes involved in the 
treatment of MRSA infections [59–185]. 
Antibiotic Class (with examples) 
Advantages 
Indications (in italics) 
Disadvantages 
SMX/TMP 
Available for oral and parenteral 
use 
Good tolerability 
Price of therapy 
Wide range of indications 
Resistance levels 
iv. infusion has to be 
administered in a large volume 
of fluid 
Tetracyclines/Glycylcyclines  
(doxycycline, tygecycline) 
Broad spectrum activity 
Wide range of indications 
(tigecycline: SSTIs, cIAI, CAP) 
Doxycycline: resistance levels 
Tygecycline: black box warning, 
iv. only 
Severe nausea and vomiting 
(dose-limiting side effect) 
Novel tetracycline-derivatives 
(eravacycline, omadacycline) 
Broad spectrum activity 
CAP, SSTIs 
Severe nausea and vomiting 
(dose-limiting side effect) 
Parenteral only 
Resistance 
expression/horizontally 
transmitted resistance genes 
Glycopeptides  
(vancomycin, teicoplainin) 
Gold standard of MRSA-therapy 
for a long time 
Extensive clinical data available 
regarding its usePrice of therapy 
Wide range of indications 
MIC creep 
Parenteral only (with 
exceptions) 
TDM required (due to 
nephrotoxicity and ototoxicity) 
Resistance expression (hVISA, 
VISA, VRSA) 
Lipoglycopeptides  
(telavancin, dalbavancin, oritavancin) 
Long half-life (single-dose 
therapy) 
Useful in OPAT 
There is no need for TDM 
 
SSTIs, bone and joint infections 
HAP, VAP (telavancin) 
Parenteral only 
Price of therapy 
Cannot be removed by dialysis 
Increased mortality in renal 
insufficiency 
Resistance 
expression/horizontally 
transmitted resistance genes 
Oxazolidinones  
(linezolid, tedizolid) 
Available for oral and parenteral 
use 
SSTIs, bone and joint infections 
Drug-drug interactions 
MAO-inhibition (Serotonin-
syndrome) 
Price of therapy 
Resistance 
expression/horizontally 
transmitted resistance genes 
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Lipopeptides  
(daptomycin) 
Bloodstream infections, infective 
endocarditis, SSTIs 
Not useful in pneumonia 
Parenteral only 
Resistance 
expression/horizontally 
transmitted resistance genes 
5th generation cephalosporins 
(ceftaroline, ceftobiprole) 
Good tolerability 
SSTIs, CAP, HAP, MRSA 
bacteremia 
Price of therapy 
Hydrolized by ESBLs (mixed 
infections) 
Resistance 
expression/horizontally 
transmitted resistance genes 
Older fluoroquinolones 
(ciprofloxacin, levofloxacin, 
moxifloxacin) 
Available for oral and parenteral 
use 
Extensive clinical data available 
regarding their use 
Good tolerability 
Accumulation in the intracellular 
space 
Price of therapy 
Broad-spectrum activity 
Wide range of indications 
Side effect profile (especially in 
light of recent developments) 
Resistance levels and rapid 
resistance development 
Next-generation fluoroquinolones 
(delafloxacin; avarofloxacin, 
finafloxacin, zaborfloxacin, 
nemonoxacin) 
 
Available for oral and parenteral 
use 
Broad-spectrum activity 
Accumulation in the intracellular 
space 
Presently studied in a wide range of 
indications (e.g., cSSTI, CAP, HAP, 
cUTI 
MDR gonorrhea) 
Black box warining 
Side effect profile 
Price of therapy 
 
Mupirocin 
Price of therapy 
Dose-dependent bactericidal 
activity 
Topical agent for MRSA nasal 
decolonization 
Additonal indications are being 
studied 
Resistance development 
Risk of toxicity when used 
orally/parenterally 
Three novel antibiotics from the lipoglycopeptide family have been approved in the period between 
2009–2014 by the US Food and Drug Administration (FDA) for the therapy of infections that are 
caused by (MDR) Gram-positive bacteria: telavancin (Vibativ®  [US]; 10 mg/kg over 8 h), dalbavancin 
(Dalvance®  [US], Xydalba®  [EU]; 1500 mg/single dose) and oritavancin (Orbactiv®  [US/EU]; 1200 
mg/single dose) [133,143]. Telavancin and oritavancin are semisynthetic derivatives of vancomycin 
with a hydrophobic side chain that is attached to the vancosamine sugar, while dalbavancin is a 
derivative of teicoplanin [133,143]. These drugs exhibit concentration-dependent antibacterial 
activity. They all show activity against hVISA/VISA, while oritavancin also exhibits antibacterial 
activity against vanA-positive S. aureus and Enterococcus spp. [144]. They are approved for 
complicated skin and skin structure infections (cSSTI), bone and joint infections, hospital-acquired 
(HAP), and ventilator-associated bacterial pneumonia (VAP) [133,143]. Their antimicrobial activity is 
attributed to a double mechanism: inhibition of cell wall synthesis (as seen previously in vancomycin) 
and the disruption of the integrity cell membrane barrier, which leads to permeabilization and cell 
death [133,143]. The antibacterial activity of these drugs is due to the novel combined action of 
inhibition of the cell wall synthesis and the disruption of bacterial cell membrane barrier function 
[145]. The additional advantage of dalbavancin and oritavancin in their long half-life (>300 h), 
therefore their half-life, coupled with their concentration-dependent activity, is appropriate for 
single-dose (once weekly) treatments, especially in OPAT settings. They do not require a loading 
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dose or TDM [133,143]. However, when compared to vancomycin, they are much more expensive, 
which currently hinders their more widespread use in clinical practice. Another potential 
disadvantage of these drugs is that, due to their high levels of plasma protein binding (PPB > 90%), 
they are not removed by conventional dialysis. An increase in the mortality rate in patients that were 
treated with renal insufficiency was also described [79,133,143]. 
The class of oxazolidinones is another important antibiotic group in the treatment of drug 
resistant Gram-positive infections. Oxazolidinones were first described in the 1970s, while the first 
drug linezolid was approved in 2000 by the FDA. Oxazolidinones were perceived as attractive drugs 
due to several features; firstly, the novel mechanism of action (inhibition of protein synthesis by 
binding to the peptidyl transferase A-site of the 50S subunit of ribosomal RNA) [146]; secondly, their 
spectrum of activity Gram-positives, including MDR strains), the option for intravenous-to-oral 
switch with excellent oral bioavailability, and the lack of cross-resistance with different antibiotics 
[147]. Linezolid (Zyvox®  [US], Zyvoxid®  [EU]; 600 mg/12 h) and tedizolid (Sivextro®  [US/EU]; 200 
mg/24 h) was approved for the treatment of nosocomial and community-acquired pneumonia, 
complicated and non-complicated skin, and soft tissue infections (including MRSA) and bone and 
joint infections, while they are not recommended for the treatment of bacteremia and endocarditis. 
Tedizolid is a prodrug (phosphate), which is hydrolyzed by plasma or intestinal enzymes in vivo to 
produce the active form of the drug [147]. Tedizolid (the second-generation oxazolidinone) has more 
potent antibacterial activity, a longer half-life (12 h), and less pronounced toxicity. Due to its higher 
(75–80%) protein binding affinity, lower doses should to be administered (cf. linezolid). They have 
high in vitro activity against MRSA; however, there are few data regarding its efficacy against 
hVISA/VISA and vancomycin-resistant S. aureus (VRSA). The drawbacks of this antibiotic group are 
related to their pharmacodynamic properties: a. drug-drug interactions, which may have severe 
consequences (e.g., due to synergism with sympathomimetic drugs (various α- and β-receptor 
agonists), their co-administration may result in an acute hypertensive episode; they increase the 
toxicity of opioid analgesics and fibrates (drugs against hyperlipidemia); they may also increase the 
pharmacological effects of insulin and oral antidiabetic drugs (like metformin and glimepiride)), b. 
serious side effects, such as serotonin-syndrome (because they can inhibit the monoamine-oxidase-A 
(MAO-A) enzyme) and myelosuppression (which may lead to hematological issues) [147,148]. Their 
clinical role in the treatment of VRSA infections is unknown due to the lack of data. The prevalence 
of oxazolidinone resistance is very low and causative mechanism includes changes in L3/L4 
ribosomal proteins and methylation of the 23S rRNA, encoded by the cfr gene [149]. Bacteria carry 
multiple copies of the genes encoding 23S rRNA; therefore, for a pronounced increase in the MIC, the 
mutation needs to be present in several copies (“gene-dose” effect) [148]. These mutations frequently 
occur in CoNS strains. The carriage of cfr does not affect tedizolid (approved in 2014) susceptibility. 
Although the endemic areas have been reported, the carriage of cfr genes continue to be very rare, 
even though it is a transmissible determinant of (presenting with a risk of developing MDR/XDR 
infections) [149]. However, some reports suggest that increasing the dose of the antibiotic could 
overcome cfr-mediated resistance (unlike mutational resistance) [148,149]. Clinical trials are currently 
underway regarding contezolid (MRX-1), which is a third-generation oxazolidinone, for the 
treatment of cSSTI, complicated intra-abdominal infections (cIAI) and cUTIs [82]. 
Daptomycin (Cubicin®  [US/EU]; 6mg/kg over 24hrs) is a lipopeptide antibiotic, which showed 
pronounced activity against various Gram-positive bacteria, including MRSA [150]. It is bactericidal, 
damaging the cell membrane and the membrane potential in a calcium-dependent fashion. It has 
been postulated that the activity of this compound is most pronounced at the division septum of 
bacteria. Daptomycin is approved for the treatment of skin and skin structure infections, bloodstream 
infections, and infective endocarditis, while it is contraindicated in pneumonia, because of its 
interaction with pulmonary surfactant [150–152]. This drug is not available for oral use, only as a 
parenteral formulation. Electrostatic repulsion of the drug molecule is thought to mediate resistance 
to daptomycin, owing to the increased positive charge of the bacterial cell surface. The gene that is 
responsible for daptomycin resistant phenotype is mpfF, which results in the incorporation of lysine 
(a positively charged amino acid) in the peptidoglycan layer: this will increase the positive charge of 
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the cell envelope, which inhibits the binding of daptomycin. In addition, genes encoding cardiolipin 
synthetases (pgsA, cls), which affect phospholipid metabolism, were also implicated [150,153]. 
Ceftaroline (Teflaro®  [US], Zinforo®  [EU]; 600 mg/12 h) and ceftobiprole (Zevtera®  [US], Mabelio®  
[EU]; 500 mg/8 h) are broad-spectrum cephalosporins with pronounced bactericidal activity against 
MRSA, VISA, daptomycin-resistant S. aureus, and vancomycin-resistant E. faecalis [154–161]. For this 
reason, they are sometimes termed anti-MRSA cephalosporins, or fifth generation cephalosporins 
[49,79]. It is important to note that these drugs are hydrolyzed by ESBL-enzymes, therefore they may 
not be appropriate for mixed infections involving Gram-positive and Gram-negative pathogens [156]. 
They have low minimum inhibitory concentrations for MRSA, which corresponds to their high 
affinity to the PBP2a/c proteins [154–160]. Ceftaroline and ceftobiprole are both approved for the 
treatment of cSSTI, CAP, and HAP (excluding ventilator-associated pneumonia), with ceftaroline 
being additionally approved for MRSA bacteremia [154–160]. Resistance to ceftaroline (with MIC 
values ≥4 μg/mL) was published, but the number of cases is very low, and the underlying mechanism 
is not yet understood [162]. An interesting therapeutic strategy involves the combination of these 
anti-MRSA cephalosporins and a glycopeptide or daptomycin (which is currently being evaluated in 
the CAMERA-2 trial) in the treatment of MRSA bacteremia, although this has been criticized for the 
increase in antibiotic use and therapeutic costs [163]. 
The role of tetracyclines in the therapy of MRSA infections has faded over the years, due to 
various mechanisms of acquired resistance [108]. There were high hopes for tigecycline (Tygacyl®  
[US/EU]; 50 mg/12 h), a broad-spectrum agent and member of glycylcycline family of drugs, which 
was approved in 2005 for the therapy of cSSSI, cIAI, CAP [164–166]. Shortly after its approval, 
tigecycline received “black box” warning from the FDA, due to the significant increase in the 
mortality of patients that were treated with tigecycline, which is in contrast to the comparator drugs 
[167]. In addition, difficulties reaching the therapeutic serum levels for bacteremia can be considered 
to be drawbacks of this drug [164–166]. Eravacycline (Xerava®  [US]) and omadacycline (approved in 
the end of 2018; Nuzyra®  [US]; 100–150 mg/24, depending on the administration form) are novel 
drugs of the tetracycline group [168–171]. They were mainly developed for the treatment of MDR 
infections, and they are not affected by resistance mechanisms that are associated with tigecycline or 
other drugs of this family. Chemically, eravacycline is closely related to tigecycline, while 
omadacycline is an aminomethylcycline-derivative [168–171]. Omadacycline is licenced for the 
treatment of CAP and SSTIs. It has a broad spectrum of activity, including many multi-drug resistant 
strains of bacteria [170,171]. Phase III studies of eravacycline for cIAI and cUTI finished recently, 
where this drug presented inferiority to levofloxacin [168,169]. During the trials of both drugs, 
therapy had to be discontinued in some cases, due to severe nausea and vomiting [168–171]. It should 
be noted that these drugs do not cover Pseudomonas aeruginosa and Proteae (Proteus, Morganella, 
Providencia); therefore, they should not be used in mixed infections where these pathogens are 
suspected. 
The clinical efficacy of some novel quinolones (avarofloxacin, finafloxacin, zaborfloxacin, 
nemonoxacin) is currently being assessed in a plethora of clinical trials for various indications, such 
as cSSTI, CAP, HAP, cUTI and sexually transmitted infections (mainly MDR gonorrhea), while 
delafloxacin (Baxdela®  [US]; 300 mg/8 h) has already been approved by the FDA for the therapy of 
cSSTI, with the evaluation of CAP and cUTI trials currently underway [172–178]. Unlike previous 
fluoroquinolones (which were zwitterionic), delafloxacin is anionic in character, which results in the 
accumulation of the drug in the intracellular space of bacteria, in phagocytes, urine, abscesses, and 
the gastic juice [173]. As these drugs are all representatives of the quinolone drug family (which has 
been a center of controversy lately, due to their side effect profile [179]), delafloxacin immediately 
received a “black box” warning by the FDA (for adverse events, such as peripheral neuropathy, 
tendinitis, C. difficile enterocolitis, and the worsening of myasthenia gravis, QTc-prolongation) and it 
is expected that the other novel drugs will receive similar designation [173]. Novel quinolones are 
broad-spectrum agents, active against fluoroquinolone (levofloxacin/moxifloxacin)-resistant 
bacteria, although some cases were reported where elevated delafloxacin MICs were observed [172–
178]. 
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Iclaprim, which is a diaminopyrimidine-type dihydrofolate-reductase (DHFR) inhibitor, is also 
being investigated for its efficacy against MRSA infections [180]. This drug-candidate was first 
developed for SSTIs; however, in the beginning 2010s, the FDA rejected further development plans 
due to QTc prolongation and the failure to show non-inferiority to the comparator drug. Following 
the subsequent acquiring of the license of iclaprim by another company, new clinical studies are 
underway. Iclaprim presented non-inferiority to vancomycin in two phase III studies targeting SSTIs, 
and a new indication for the drug (therapy of S. aureus infections in cystic fibrosis patients); 
nonetheless, the side effect profile, which is associated with prolonged use (liver toxicity), is 
concerning [127,181]. The dose used in these trials was 80 mg/12 hours. Iclaprim is not affected by the 
resistance mechanisms, which hindered the use of SMX/TMP previously [45,124,125]. 
Mupirocin (Bactroban®  [US/EU]) is used as a topical agent for the nasal decolonization of MRSA 
patients; in addition, it received a new indication for the topical therapy of impetigo [88,182]. The 
mechanism of action is through binding bacterial isoleucyl tRNA synthetase, resulting in the 
inhibition of protein synthesis. Resistance to mupirocin has been described: low-level resistance is 
characterized by point mutations in the ileS gene, in contrast, high-level resistance is plasmid-
mediated (mupA gene), which code for a mutant isoleucyl tRNA synthetase, to which mupirocin is 
unable to bind [88,183]. 
Fusidic acid is another drug that was mainly used as a topical preparation for the treatment of 
skin infections (alone or in combination with topical steroids), atopic dermatitis, and in eye drops, in 
addition to MRSA decolonization (in combination with rifampicin) in the case of mupirocin resistance 
[49,88]. The safety and efficacy of fusidic acid orally or intravenously (as it is available in both forms) 
has also been demonstrated in combination with other antibiotics (e.g., vancomycin, gentamycin, 
levofloxacin) in the therapy of severe staphylococcal/MRSA-infections, typically in complicated 
SSTIs, osteomyelitis, and septic arthritis, owing to the excellent penetration of this drug into skin 
blisters, joints, and the bone tissue [184,185]. Unfortunately, resistance frequently emerges against 
this steroid-based antibiotic, particularly after prolonged therapy; the resistance levels are range 
between 0.3–64% worldwide, with significant variation in the prevalence of various resistance 
determinants in different geographical region [49,88]. This phenomenon is especially frequent in the 
CA-MRSA isolates, being mediated by the mutations in the chromosomal fusA (encoding elongation 
factor G) or rplF (or FusE, encoding ribosome protein L6) genes, or the acquision of the transferable 
fusB, fusC or fusD genes (protection of drug target site) [184,185]. When it comes to its antimicrobial 
mechanism of action, fusidic acid is a protein synthesis inhibitor, which interferes with ribosomal 
translation. Around 90% of the drug binds to the plasma proteins and the elimination half-life is 
around 8–10 hours [88]. Currently, there are Phase II studies underway evaluating its efficacy in cSSTI 
and bone-joint infection [184,185]. 
Pleuromutilin derivatives are well known drugs since the 1950s, with valnemulin and tiamulin 
being used routinely in veterinary medicine worldwide [186]. These drugs are inhibitors of protein 
synthesis, acting on the 50S ribosomal subunit (binding to peptidyl-transferase on the 23S rRNA). At 
the time of their discovery, azamulin was the primary drug candidate, but, due to its pronounced 
effect on the liver microsomal enzymes (CYP inhibitor), liver toxicity, and the availability of drugs 
with more advantageous properties, its development was discontinued [186]. Nevertheless, in the 
current age of MDR pathogens, there is a fresh interest in pleuromutilin-type antimicrobials for 
human use. Retapamulin (Altrabax® , Altargo®  [US]) was the first class of these drugs to receive 
approval from the FDA, and it is currently used as a topical antibiotic (for the treatment of impetigo) 
[187–189]. There is interest in retapamulin to be used in decolonization regimens for MRSA as cross-
resistance with mupirocin is unlikely, although clinical trials are needed to assess the value of this 
drug in the abovementioned indication [190]. Besides retapamilin, azamulin and lefamulin are too in 
the clinical (Phase II) phase of drug development in SSTIs and CAP that is caused by MDR Gram-
positive bacteria [186]. 
Various emerging therapeutic approaches are currently in development for the treatment of 
MRSA and other related MDR infections, including antimicrobial peptides (AMPs, such as magainin, 
pexiganan) [191,192], quorum sensing-inhibitors (or quorum quenchers) [23], inhibitors of virulence 
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factor-expression [193–195], efflux pump inhibitors [132,196,197], probiotics [193], repurposed 
natural compounds with antimicrobial activity (predominantly for topical use) [198,199], phage 
therapy [200,201], and the development of anti-staphylococcal vaccines [202,203]. There are 
numerous studies that indicate the promise of combating MRSA infections with AMPs; their 
mechanism of action mainly consists of creating pores on in the intact bacterial membrane, which 
leads to cell lysis [191,192,204]. However, there have been many difficulties (e.g., lack of stability in 
vivo, immunogenicity, toxicity to red blood cells, enzymatic degradation) in their translation to 
clinical use [191,192]. Peptidomimetics are de novo synthesized or modified peptide sequences with 
enhanced antibacterial potency and the lack of the disadvantages of the native peptides, which are 
currently in development [205–207]. Brilacidin is a defensin mimetic (defensins are antimicrobial 
peptides in vertebrates, which are predominantly found in neutrophil granulocytes; they have 
important roles in innate immunity [208]), which has broad-spectrum antibacterial activity 
[151,192,209]. This peptide affects the bacterial cell membrane in a similar fashion to daptomycin 
[151]. The main advantage of brilacidin is that it also exerts antimicrobial activity against the non-
replicating, dormant forms (in case of S. aureus, small-colony variants) of bacteria [151,192,209]. 
Brilacidin is currently enrolled in Phase II. trials for the treatment of SSTIs and oral mucositis [192]. 
The therapeutic application of phages in the treatment of infectious diseases has been around since 
prior to the rise of antibiotics [200,201,210]. Due to the increase of MDR-infections, many people 
consider these bacteria-specific viruses to be potential therapeutic alternatives. There is an increasing 
number of case reports, where a seemingly untreatable infection (usually due to pan-resistant 
Enterobacteriaceae) was cured by the application of phages, therefore it would be valid to assume that 
they could also have significance in the treatment of MRSA infections. Although the regulatory 
environment is not yet defined, phages and artilysins (phage-derived lytic proteins) may be useful in 
MRSA-associated SSTIs. However, for their widespread use, an appropriate formulation for 
oral/parenteral use and the precise composition of effective phages/enzymes needs to be defined 
beforehand [200,201,210,211]. Novel drug targets include FabI inhibitors (FabI or enoyl-ACP-
reductase is a key enzyme of unsaturated fatty acid synthesis in bacteria [212]), such as Debio 1452 
and its prodrug Debio 1450 (or afabicin), which are in Phase II trials for the therapy of SSTIs that are 
caused by methicillin-susceptible and resistant S. aureus [11,213]. Many researchers are interested in 
the development of metal-based nanoparticles (NPs) with antimicrobial properties for use in MRSA 
infections [214]. Various NPs containing different metals (titanium, magnesium, gold, silver, zinc, 
copper, bismuth, etc.) showed promising activity against this pathogen, even though the penetration 
of S. aureus biofilms, while others (such as aluminum) were not recommended, based on experimental 
results. These studies predominantly administered these nanoparticles in some hydrogel form (i.e., 
for external use) or on the surface of an implanted medical device [215–218]. 
There were high hopes for the development of broad-spectrum, anti-MRSA/VRE carbapenems 
(e.g., tomopenem, razupenem), which bypassed the resistance that is caused by the modified PBPs 
and retaining their activity against Gram-negative organisms, however none of these agents thus 
passed onto clinical trials [219–221]. The closest thing in development with broad-spectrum activity 
is ceftaroline/avibactam, which is a combination of the anti-MRSA cephalosporin and a non-β-lactam-
type β-lactamase-inhibitor [222,223]. 
New and emerging oligonucleotide-based antibacterial strategies, such as RNA-interference 
(RNAi), aptamers (single strand nucleic acids; ssRNA or ssDNA), and the use of CRISPR/Cas 
(clustered, regularly interspaced, short palindromic repeats, and CRISPR-associated protein 9, 
respectively) against MRSA and other MDR pathogens are also intensively studied, however, these 
are probably decades away from potential real-life applications [214,224,225]. The extremely high 
costs and risk-to-benefit ratio (which is especially high to antimicrobial research) is discouraging 
pharmaceutical companies to invest in studies targeting antibiotics, especially because, in addition to 
the physico-chemical characteristics, formulation, and adverse events of these compounds, 
companies have to keep in mind that microorganisms will develop resistance sooner or later, like in 
any facet of drug design and development [40,198,226–228]. Unfortunately, this is a general concern 
involving all MDR bacteria, not only MRSA, where clinicians are facing worsening odds to provide 
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their patients with adequate therapy [35,80,81]. Additionally, some of these compounds are protein-
based, therefore the potential for hypersensitivity and parenteral-only administration are additional 
hindering factors [203,229]. The development of novel antibiotics may be further complicated by their 
potential to affect the normal intestinal microbiota (i.e., their “ecological impact”). Drugs that kill the 
gut microbiota may select for C. difficile, VRE, ESBL-, and carbapenemase-producing 
Enterobacteriaceae, leading to additional issues for the patients in the future [230]. 
5. Concluding Remarks 
S. aureus is a fine example of a successful pathogen, which was able to morph and adapt with 
such tenacity to the changing landscape of modern medical interventions (e.g., implanted devices, 
catheters) and the available antimicrobial agents. Penicillin-, methicillin-, (and to a lesser extent) 
vancomycin-resistant strains of staphylococci appeared one after another due to the selection 
pressure, proving that the antibiotic “arms race” is very real, and humanity as a whole is still on the 
losing side. MRSA infections emerged in nosocomial settings; however, in the 21st century, the 
infections that were acquired in the community setting are a more pressing concern. MRSA is still an 
important factor of mortality (especially as a causative agent of endocarditis and bacteremia) all 
around the globe. Vigilant screening may reduce the number of patients where carriage turns into 
infection, while typing is useful in obtaining information pertaining to the local and global 
epidemiology, and the spread of successful clones. Alternative therapeutic modalities for MRSA are, 
in fact, being developed, though with no time-frame or guarantee that they will be successful in a 
clinical evaluation. One would argue that the current therapeutic armamentarium (and the number 
of drugs in development) could provide us with temporary safety; however, this hubris could also 
lead to the demise of the healthcare system, as we know it. 
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Abbreviations 
Abbreviations Full 
AST antimicrobial susceptibility testing 
CA community-acquired; CAMERA 
CAMERA 
combination antibiotic therapy for methicillin-resistant  
Staphylococcus aureus infection (clinical trial) 
CAP community-acquired pneumonia 
CC clonal complex 
CDC US Centers for Disease Control and Prevention 
cgMLST core genome multi-locus sequence typing 
CLSI Clinical and Laboratory Standards Institute 
CoNS coagulase-negative Staphylococcus 
CO-MRSA community-onset MRSA 
CRISPR/Cas9 
lustered regularly interspaced short  
palindromic repeats/CRISPR associated protein 9 
CYP cytochrome P450 
DHFR dihydrofolate-reductase 
ESBL extended-spectrum β-lactamase 
ESCMID 
European Society of Clinical Microbiology  
and Infectious Diseases 
EU European Union 
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EUCAST 
European Committee on  
Antimicrobial Susceptibility Testing 
FDA US Food and Drug Administration 
HA hospital-associated 
HAP hospital-acquired pneumonia 
hVISA heterogeneous vancomycin-intermediate S. aureus 
HLA human leukocyte antigen 
IAI intra-abdominal infection 
LA livestock-associated 
MALDI-TOF MS 
matrix-assisted laser desorption/ionization  
time-of-flight mass spectrometry 
MAO-A monoamine-oxidase-A 
MFS major facilitator superfamily 
MDR multidrug-resistant 
MIC minimal inhibitory concentration 
MLST multi-locus sequence typing 
MRSA methicillin/oxacillin-resistant S. aureus 
NGS next-generation sequencing 
NP nanoparticle 
OPAT outpatient parenteral antibiotic therapy 
PFGE pulse-field gel electrophoresis 
PBP penicillin-binding protein 
QS quorum sensing 
UTI urinary tract infection 
PDI prosthetic device infection 
PCR polymerase chain reaction 
PVL Panton–Valentine leucocidin 
QRDR quinolone resistance-determining region 
QTc corrected QT-interval 
RNA ribonucleic acid 
RNAi RNA-interference 
SCV small-colony variant 
SMX/TMP co-trimoxazole 
SSTI skin and soft tissue infection 
ST sequence type 
ssDNA single-strand DNA 
ssRNA single-strand RNA 
TDM therapeutic drug monitoring 
TAT turnaround time 
TLR toll-like receptor 
TSS toxic shock syndrome 
TSST toxic shock syndrome toxin 
UTI urinary tract infection 
VAP ventilator-associated pneumonia 
VISA vancomycin-intermediate S. aureus 
VNTR variable number tandem repeat 
VRE vancomycin-resistant enterococci 
VRSA vancomycin-resistant S. aureus 
WGS whole-genome sequencing 
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